Post-Activity Test and Activity Evaluation

POST TEST

Question Title

1. Which of the following is the most common carbapenemase identified in the United States? (Required.)

K. pneumoniae carbapenemase (KPC)

New Delhi metallo-beta-lactamase (NDM)

Verona integrin-encoded (VIM)

Imipenemase (IMP)

Question Title

2. Carbapenem resistance by P. aeruginosa in the US is most frequently associated with: (Required.)

NDM carbapenemase

OXA-48-type carbapenemase

VIM carbapenemase

A non-carbapenemase-producing mechanism

Question Title

3. Pneumonia that occurs at least 48 hours after initiating mechanical ventilation is called: (Required.)

Severe CAP

HAP

Ventilated HAP

VAP

Question Title

4. The most common pathogens for HAP/VAP include all of the following except: (Required.)

S. aureus

S. pneumoniae

P. aeruginosa

K. pneumoniae

Question Title

5. Newer beta-lactamase inhibitors (e.g., avibactam, vaborbactam) are effective against all of the following beta-lactamases except: (Required.)

ESBLs

Class A carbapenemases (e.g., KPCs)

Class B metallo-beta-lactamases

ampC beta-lactamases

Question Title

6. Which of the following agents exhibits the greatest in vitro activity against MDR P. aeruginosa? (Required.)

Delafloxacin

Ceftolozane-tazobactam

Ceftazidime-avibactam

Eravacycline

Question Title

7. The REPROVE trial that compared ceftazidime-avibactam versus meropenem for nosocomial pneumonia demonstrated all of the following except: (Required.)

Similar clinical cure rates in the overall patient population

Similar clinical cure rates among patients with VAP

Superiority of ceftazidime-avibactam over meropenem in clinical cure rates against infections caused by P. aeruginosa

Similar clinical cure rates among patients with infections caused by K. pneumoniae

Question Title

8. All of the following are correct regarding the ASPECT-NP trial comparing ceftolozane-tazobactam against meropenem for nosocomial pneumonia EXCEPT? (Required.)

P. aeruginosa comprised approximately 25% of the pathogens identified

Approximately one-third of participants were ventilated

Overall 28-day all-cause mortality rates were similar between treatment groups

Overall clinical cure rates were similar between treatment groups

Question Title

* 1. Which of the following is the most common carbapenemase identified in the United States? (Required.)

Question Title

* 2. Carbapenem resistance by P. aeruginosa in the US is most frequently associated with: (Required.)

Question Title

* 3. Pneumonia that occurs at least 48 hours after initiating mechanical ventilation is called: (Required.)

Question Title

* 4. The most common pathogens for HAP/VAP include all of the following except: (Required.)

Question Title

* 5. Newer beta-lactamase inhibitors (e.g., avibactam, vaborbactam) are effective against all of the following beta-lactamases except: (Required.)

Question Title

* 6. Which of the following agents exhibits the greatest in vitro activity against MDR P. aeruginosa? (Required.)

Question Title

* 7. The REPROVE trial that compared ceftazidime-avibactam versus meropenem for nosocomial pneumonia demonstrated all of the following except: (Required.)

Question Title

* 8. All of the following are correct regarding the ASPECT-NP trial comparing ceftolozane-tazobactam against meropenem for nosocomial pneumonia EXCEPT? (Required.)

1. Which of the following is the most common carbapenemase identified in the United States? (Required.)

2. Carbapenem resistance by P. aeruginosa in the US is most frequently associated with: (Required.)

3. Pneumonia that occurs at least 48 hours after initiating mechanical ventilation is called: (Required.)

4. The most common pathogens for HAP/VAP include all of the following except: (Required.)

5. Newer beta-lactamase inhibitors (e.g., avibactam, vaborbactam) are effective against all of the following beta-lactamases except: (Required.)

6. Which of the following agents exhibits the greatest in vitro activity against MDR P. aeruginosa? (Required.)

7. The REPROVE trial that compared ceftazidime-avibactam versus meropenem for nosocomial pneumonia demonstrated all of the following except: (Required.)

8. All of the following are correct regarding the ASPECT-NP trial comparing ceftolozane-tazobactam against meropenem for nosocomial pneumonia EXCEPT? (Required.)